TG Therapeutics (TGTX) Expected to Announce Quarterly Earnings on Monday

TG Therapeutics (NASDAQ:TGTX) is expected to issue its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect the company to post earnings of $0.3171 per share and revenue of $229.7160 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 3, 2026 at 8:30 AM ET.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The company had revenue of $204.92 million during the quarter, compared to the consensus estimate of $200.33 million. During the same quarter last year, the company earned $0.03 earnings per share. The business’s revenue was up 69.5% on a year-over-year basis. On average, analysts expect TG Therapeutics to post $1 EPS for the current fiscal year and $3 EPS for the next fiscal year.

TG Therapeutics Stock Performance

TG Therapeutics stock opened at $56.04 on Monday. The firm has a market capitalization of $8.58 billion, a P/E ratio of 19.59, a P/E/G ratio of 1.40 and a beta of 1.60. The stock has a fifty day moving average price of $49.02 and a two-hundred day moving average price of $38.07. TG Therapeutics has a 52-week low of $25.28 and a 52-week high of $59.30. The company has a debt-to-equity ratio of 1.28, a current ratio of 5.81 and a quick ratio of 5.12.

Institutional Trading of TG Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TGTX. State Street Corp raised its holdings in shares of TG Therapeutics by 4.7% in the fourth quarter. State Street Corp now owns 8,479,999 shares of the biopharmaceutical company’s stock valued at $252,789,000 after buying an additional 379,380 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in TG Therapeutics by 35.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,051,132 shares of the biopharmaceutical company’s stock worth $61,144,000 after buying an additional 531,759 shares in the last quarter. Invesco Ltd. grew its holdings in TG Therapeutics by 47.1% during the 4th quarter. Invesco Ltd. now owns 1,609,815 shares of the biopharmaceutical company’s stock worth $47,989,000 after acquiring an additional 515,481 shares during the last quarter. Man Group plc grew its holdings in TG Therapeutics by 621.5% during the 3rd quarter. Man Group plc now owns 1,008,462 shares of the biopharmaceutical company’s stock worth $36,431,000 after acquiring an additional 868,697 shares during the last quarter. Finally, Nuveen LLC increased its position in TG Therapeutics by 34.1% in the 4th quarter. Nuveen LLC now owns 953,206 shares of the biopharmaceutical company’s stock valued at $28,415,000 after acquiring an additional 242,434 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Weiss Ratings raised shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, May 1st. Jefferies Financial Group reissued a “buy” rating and set a $83.00 price target on shares of TG Therapeutics in a report on Monday, June 22nd. Zacks Research upgraded shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. Bank of America upped their price objective on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a research note on Tuesday, July 7th. Finally, HC Wainwright raised their price objective on shares of TG Therapeutics from $70.00 to $77.00 and gave the stock a “buy” rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $53.33.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.